Scientific Online Resource System


Obesity related alterations in pharmacokinetics and pharmacodynamics of drugs: emerging clinical implications in obese patients - part II

Istvan G. Telessy, Harpal S. Buttar


Key words: ADME, overweight, obesity, pharmacokinetics, pharmacodynamics, drug dose adjustment, obese patients

Full Text


Klotz U. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet 1976; 1: 204-218.

Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci 1982; 71(8): 942-844.

Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1982; 7: 108-124.

Galletti F, Fasano ML, Ferrara LA, et al. Obesity and betablockers: influence of body fat on their kinetics and cardiovascular effects. J Clin Pharmacol 1989; 29: 212-216.

Corcoran GB, Salazar DE, Sorge CL. Pharmacokinetic characteristics of the obese overfed rat. Int J Obes 1989; 13:69-79.

Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 25: 103-114.

Wurtz R, Itokazu G, Rodvold K. Antimictobial dosing in obese patients. Clin Infect Dis 1997; 25: 112-118.

Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. J Clin

Pharmacol 1983; 23: 369-376.

Kumana CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokineics in Chinese and in white Caucasians - relation to body lipid stores. Eur J Clin Pharmacol 1987; 32: 211-215.

Zhou Xin, Rougée LRA, Bedwell DW et al. Difference in the pharmacokinetics and hepatic metabolism of anti-diabetic drugs in Zucker Diabetic Fatty and Sprague-Dawley rats. Drug Metab Dispos 2016; DOI: 10.1124/dmd.116.070623.

Lutz TA, Woods SC. Overview of animal models of obesity. Curr Protoc Pharmacol 2012; Chapter: Unit5:61.


Behnke AR, Osserman EF, Welham WC. Lean body mass; its clinical significance and estimation from excess fat and total body water determinations. AMA Arch Intern Med 1953; 91(5): 585-601.

Hume R. Prediction of lean body mass from height and weight. J Clin Path 1966; 19:389-391.

Janmahasatian S, Duffull SB, Ash S. Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin

Pharmacokinet 2005; 44(10): 1051-1065.

Green, B, Duffull SB. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Phaemacol Ther 2002;72(6): 743-744.

De Baerdemaeker LEC, Mortier, EP, Struys MMRF. Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain 2004;4(5): 152-156. DOU 10.1093/bjaceaccp/mkh042

Beckman LM, Boullata JI, Fischer PL, et al. Evaluation of lean body weight equation by dual-energy X-ray absorptiometry measures. J Parenter Enteral Nutr 2017; 41: 392-397.

Carasco CF, Fletcher P, Maconochie I. Review of commonly used age-based weight estimation for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs. Br J Clin Pharmacol 2015; 81:849-856.

Moisey LL, Mourtzakis M, Kozar RA, et al. Existing equations to estimate lean body mass are not accurate int he critically ill: results of a multicenter observational study. Clin Nutr 2016; DOI: 10.1016/j.clnu.2016.09.013.

Augustemak de Lima LR, Custodio Martins P, Alencar Souza Alves Junior C., Chula de Castro JA, Santos Silva DA, Petroski EL. Are traditional body fat equations and anthropometry valid to estimate body fat in children and adolescents living with HIV? Braz J Infect Dis 2017; 735 1-9. DOI:10.1016/j.bjid. 2017.03.015.

MacMahon SW, WilckenDE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in 21young, overweight hypertensive patients. N Eng J Med 1986; 314: 334-339.

Redinger RN. The pathophysiology of obesity and its clinical manifestation. Gastroenterol Hepatol 2007; 3: 856-863.

Buechler C, Weiss TS. Does hepatic steathosis affect drug metabolizing enzymes in the liver? Curr Drug Metab 2011; 12: 24-34.

Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity in the pharmacokinetics of drugs in humans. Clin

Pharmacokinet 2010; 49: 71-87.

Cheymol G. Effects of obesity on pharmacokinetics. Implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-231.

Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr: Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicron Agents Chemother 1982. 21(4): 575-580.

Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45: 48-56.

Rich BS, Keel R, Ho VP, et al. Cefepirime dosing in the morbidly obese patient population. Obes Surg 2012; 22(3): 465-471.

Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic tartet attainment of ertapenem in normal-weight, obese, and extremly obese adults. Antimicrob Agents Chemother 2006; 50(4): 1222-1227.

Allard S, Kinzig M, Boivin G, et al. Intravenous ciprofloxacin disposition in obese. Clin Pharmacol Ther 1993; 54(4): 368-373.

Cook AM, Martin C, Adams VR, Morehead ES. Pharmacokinetics of intravenous levofloxacin administered

milligrams in obese adults. Antimicrob Agents Chemother 2011; 55(7): 3240-3243. DOI: 10.1128/AAC.01680-10

Toma O, Suntrup P, Stefanescu S, et al. Pharmcokinetics and tissue penetrationof cefoxitin in obesity: implications for risk of surgical site infection. Anest Analg 2011; 113((4): 730-737.

Van Kralingen S, van de Garde EM, Knibbe CA, et al. Comparative evaluation of atracurium dosen in ideal body weight vs. Total body weight in morbidly obese patients. Br J Clin Pharmacol 2011; 71:34-40.

Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender and obesity on midazolam kinetics.

Anesthesiology 1984; 61(1): 27-35.

Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anest Analg 1992; 74:515-518.

Jung D, Meyersohn M, Perrier D, Calkins J, Saunders R.: Thiopental disposition in lean and obese patients undergoing surgery. Anaesthesiology 1982; 56(4): 269-274.

Egan TD, Huizinga B, Gupta SK, et al. Remifentanyl pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89(3): 562-573.

Schwartz AE, MatteoRS, Ornstein E et al. Pharmacokinetics of sufentanyl in obese patients. Anesth Analg 1991; 73: 790-793.

Servin F, Farinotti R, Haberer HP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anaesthesiology 1993; 78(4): 657-665.

Leclercq I, Horsmans Y, Desager JP, et al. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998; 28:410-416.

O`Shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-367.

Hunt CM, Watkins PB, Seanger I, et al. Heterogenity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992; 51: 18-23.

Kotlyar M, Carson SW. Effect of obesity ont he cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37: 9-19.

Flockhart, DA. Drug interactions and cytochrom P450 system: the role of cytochrom P450 2C19. Clin Pharmacokinet 1995; 29 (Suppl. 1):45-52.

Moffett BS, Bomgaars LR. Response to warfarin therapy in obese pediatric patients dosed according to institutional guidelines. J Pediatr Hematol Oncol 2014; 36: e487-479. DOI 10.1097/MPH.0000000000000087.

Hart R, Veenstra DL, Boudreau DM, Roth JA. Impact of body mass index and genetics on warfarin major bleeding outcomes in a community setting. Am J Med 2017; 130(2):222-228. DOI: 10.1016/j.amjmed.2016.08.017.

Kinoshita T, Honma S, Shibata Y, et al. An innovative LCMS/ MS-based method for determining CYP17 and CYP19 activity in the adipose tissue of pre- and post-menopausal and ovariectomized women using 13C-labelled steroid substrates. J Clin Endocrinol Metab 2014; 99:1339-1347.

Yanev S, Chaldakov GN. Adipotoxicology of obesity and related diseases. Biomed Rev 2012; 23: 53-60.

Matthew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diab Rev 2011; 7: 41-49.

Chang Y., Ryu S, Choi Y, et al. Metabolically healthy obesity and development of chronic kidney disease: a cohort study. Ann Intern Med 2016; 164: 305-312.

Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17(5): 610-615.

Bouquegneau A, Vidal-Petiot E,Moranne O, et al. Creatinine-based equations for the adjustment of drug

dosage in an obese population. Brit J Clin Pharmacol 2015; 81(2): 349-361.

Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 1981; 102: 740-744.

Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004; 38: 31-35.

Ye J. Adipose tissue vascularization: its role in chronic inflammation. Curr Diab Rep 2011; 11: 203-210 DOI: 1.1007/s11892-011-0183-1.

Sparreboom A, Wolff AC, Mathijssen RHJ, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 26: 4707-4713.

Pai MP, Coiutti P, Pea F. Levofloxacin dosing regimen in severly morbidly obese patients (BMI 40 kg/m2) should be guided by creatinin clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. Clin Pharmacokinet 2014; 53: 753-762.

Schröder A, Klein K, Winter S, et al. Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J 2013; 13:12-20.

Chaldakov GN, Stankulov IL, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Design 2003; 9:1023-1031.

Pasquali R, Ambrosi B, Armanini D, et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentration: a dose-response study. J Clin Endocrinol Metab 2002; 87: 166-175.

Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007; 8 (1):21-34.

Sarlis NJ, Gourgiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 439-448.

Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults adolescents and children. CPT:Pharmacometrics Syst Pharmacol 2013; 2, e72 DOI: 10.1038/psp.2013.47

Leeder JS, Meibohm B. Challenges and opportunities for increaseing the knowledge base related to drug biotransformation and pharmacokinetics during growth and development. Drug Metab Dispos 2016; 44 (7): 916-923. DOI: 10.1124/dmd.116.071159.

Geens T, Neels H., Covaci A. Distribution of bisphenol-A, triclosan and n-nonylphenol in human adipose tissue, liver and brain Chemosphere 2012; 87(7): 796-802.

Shi H, Senthil Kumar SP, Liu X. G Protein-couled estrogen receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Trans Sci 2013; 114: 193-250.

Hall JE, do Carmo JM, da Silva AA. et al. Obesity-induces hypertension: interaction of neurohormonal and renal mechanisms. Circ Res 2015; 116(6): 991-1006.

Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010; 81(6):474-480. DOI: 10.1016/j.contraception.2010.01.016.

Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80(2):119-127. DOI: 10.1016/j.contraception.2009.04.011.

Dragoman M, Petrie K, Torgal A, et al. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception 2013; 87(4):432- 436. doi: 10.1016/j.contraception. 2012.12.001.

Robinson JA, Burke AE. Obesity and hormonal contraceptives efficacy. Womens Health (London, Engl) 2013; 9 (5): 453-466.

Cochrane Database of Systematic Reviews: Hormones for birth control in overweight or obese women 2016; DOI: 10.1002/14651858.CD008452.pub4.

Majer-Lobodzinska A, Adamiec-Mroczek J. Glucocorticoid receptor polymorphism in obesity and glucose homeostasis. Adv Clin Exp Med 2017; 26(1): 143-148. DOI: 10.17219/acem/41231

Barton M, Filardo EJ, Lolait SJ, et al. Twenty years of the G protein-coupled estrogen receptor GPER: historical and personal perspectives. J Steroid Biochem Mol Biol 2017; DOI: 10.1016/j-jsbmb.2017.03.021. pii: S0960-0760(17)30086-9

Jaramillo-Morales OA, Espinoza-Juarez JV, Garcia-Martinez BA, Lopez-Munoz FJ. Ketoprofen and antinoniception in hypo-oestrogenic Wistar rats fed on a high sucrose diet. Eur J Pharmacol 2016; 788: 168.175. DOI: 10.1016/jejphar.2016.06.030.

Rosas J, Llinares-Tello F, Senabre-Gallego JM, et al. Obesitydecreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 2017; 35: 145-148.

Cho WJ, Lee DK, Lee SY, et al. Diet-induced obesity reduce the production of influenza vaccine-induced antibodies via impaired macrophage function. Acta Virol 2016; 60(3): 298-306.

Kou FC, Huang YH, Lin FH, et al. Circulating soluble IL-6 receptor concentration and visceral adipocyte size are related to insulin resistance in Taiwanese adults with morbid obesity. Metabol Syndr Relat Disord 2017; 15(4): 187-193. DOI: 10.1089/met.2016.01.0135.



Article Tools
Email this article (Login required)
About The Authors

Istvan G. Telessy
University of Pécs, Faculty of Pharmacy, Pécs

Department of Pharmaceutics

Harpal S. Buttar
University of Ottawa, School of Medicine, Ottawa, Ontario

Department of Pathology and Laboratory Medicine

Font Size